Thermo Fisher Scientific IGFBP5 Polyclonal Antibody, PeproTech

Applications and Tested Dilution

Product Specifications

Product Specific Information

AA Sequence of recombinant protein:
MLGSFVHCEP CDEKALSMCP PSPLGCELVK EPGCGCCMTC ALAEGQSCGV YTERCAQGLR CLPRQDEEKP LHALLHGRGV CLNEKSYREQ VKIERDSREH EEPTTSEMAE ETYSPKIFRP KHTRISELKA EAVKKDRRKK LTQSKFVGGA ENTAHPRIIS APEMRQESEQ GPCRRHMEAS LQELKASPRM VPRAVYLPNC DRKGFYKRKQ CKPSRGRKRG ICWCVDKYGM KLPGMEYVDG DFQCHTFDSS NVS.

Preparation:
Produced from sera of rabbits immunized with highly pure Recombinant Human IGF-BP5. Anti-Human IGF-BP5-specific antibody was purified by affinity chromatography employing an immobilized Human IGF-BP5 matrix.

Sandwich ELISA:
To detect Human IGF-BP5 by sandwich ELISA (using 100 µL/well antibody solution), a concentration of 0.5–2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human IGF-BP5 (500-P232Bt) as a detection antibody, allows the detection of at least 0.2–0.4 ng/well of Recombinant Human IGF-BP5.

Western Blot:
To detect Human IGF-BP5 by Western Blot analysis, this antibody can be used at a concentration of 0.1–0.2 µg/mL. Used in conjunction with compatible secondary reagents, the detection limit for Recombinant Human IGF-BP5 is 1.5–3.0 ng/lane, under either reducing or non-reducing conditions.

Target Information

The insulin-like growth factor-binding proteins (IGFBPs) are a family of homologous proteins that co-evolved with IGFs. They function as shuttle molecules for soluble IGFs and regulate IGF signaling. IGFBPs influence IGF bioavailability, concentration, and distribution in the extracellular environment, and may also have biological activities independent of IGFs.
Seven IGFBPs have been described, each differing in tissue distribution, half-life, and modulation of IGF interactions. IGFBP1 is negatively regulated by insulin and expressed during fetal liver development. IGFBP2 acts as a chaperone escorting IGFs to target tissues. IGFBP3 is the most abundant, complexed with ~80% of serum IGFs. IGFBP4 is released by dermal fibroblasts upon injury. IGFBP5 is secreted by myoblasts and may play a key role in muscle differentiation.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.